Previous studies suggest increased cGMP levels may interact in modulating hypoxic stimulation of erythropoietin (EPO) production.39,40 Likewise, post-stroke treatment with erythropoietin showed neuroprotective effects in cerebral ischemia41 by reducing neuroinflammation42 and promoting synaptic plasticity.43 Therefore, pharmacological treatment post-stroke using sGC activators may also stimulate erythropoietin production leading to a secondary neuroprotective pathway. The gene discussed is SGCB; the disease is stroke disorder.